AlloSeq cfDNA is a kit-based blood test that measures the amount of donor-derived cell-free DNA (dd-cfDNA) in a transplant recipient to help determine the health of the transplanted organ. It is currently only available outside of the United States.
The kit is designed to allow your laboratory to implement the AlloSeq cfDNA surveillance solution.
The kit is designed to allow your laboratory to implement the AlloSeq cfDNA surveillance solution
Cell-free DNA is fragmented DNA originating from cells and continuously released into the bloodstream
AlloSeq cfDNA measures cfDNA, and uses single nucleotide polymorphisms (SNPs) to distinguish between donor and recipient.
AlloSeq can quantify increasing levels of dd-cfDNA, serving as a leading indicator of graft injury
AlloSure is a dd-cfDNA surveillance service that is clinically and analytically validated for identifying kidney injury
AlloSure was clinically validated in the prospective, multi-center DART study conducted across 14 transplant centers across the United States. DART and over twenty subsequent publications and abstracts have demonstrated that AlloSure surveillance provides actionable information for patient management: High NPV gives peace of mind to physicians and patients.